NCT07011511View on ClinicalTrials.gov

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 2, 2027

Study Completion Date

December 2, 2027

Conditions
Malaria, Falciparum
Interventions
DRUG

MMV055 Dose 1

40mg

DRUG

MMV055 Dose 2

100mg

DRUG

MMV055 Dose 3

200mg

DRUG

MMV055 Dose 4

400mg

DRUG

MMV055 Dose 5

800mg

DRUG

MMV055 Dose 6

TBCmg

DRUG

Matching placebo Part A

Part A

DRUG

Matching placebo Part B

Part B

COMBINATION_PRODUCT

MMV055/MMV371 Combo 1

Combination 1

COMBINATION_PRODUCT

MMV055/MM371 Combo 2

Combination 2

COMBINATION_PRODUCT

MMV055/MMV371 Combo 3

Combination 3

Trial Locations (1)

NG11 6JS

RECRUITING

Quotient Sciences, Nottingham

All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

collaborator

The Doctors Laboratory Ltd

INDUSTRY

lead

Medicines for Malaria Venture

OTHER